SlideShare a Scribd company logo
1 of 48
Download to read offline
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Free to Choose? Reform and Demand Response in
the British National Health Service
Martin Gaynorāˆ— Carol Propper Stephan Seiler
āˆ—Carnegie Mellon University, University of Bristol and NBER
Imperial College, University of Bristol and CEPR
Stanford University and CEPR
Nuļ¬ƒeld Trust
13 September 2013
Gaynor, Propper, Seiler Free to Choose? Page 1 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Questions
What We Do
Big Question
What is impact of competition on quality in health care
markets?
US relies on marketsand reforms outside the US seek to
expand choice using markets.
Big deal - quality of care can have a big impact on welfare.
We know something about the impact of market structure on
quality (e.g., Kessler and McClellan, 2000; Cutler, Huckman,
Kolstad, 2010; Cooper, Gibbons, Jones, McGuire, 2010;
Gaynor, Moreno- Serra, Propper, 2010).
But donā€™t know much about the mechanisms by which this
occurs.
Gaynor, Propper, Seiler Free to Choose? Page 2 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Questions
What We Do
Big Question cont
In economic models standard that ļ¬rmsā€™ demands become
more elastic with the # of ļ¬rms, i.e. with more consumer
choice.
A necessary condition for competition to get tougher with the
# of ļ¬rms.
Many policies rest on assumption that choice will provide
beneļ¬ts by forcing providers to compete for patients and so
respond to consumer preferences.
But little direct testing of this.
Gaynor, Propper, Seiler Free to Choose? Page 3 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Questions
What We Do
Our Question
Directly examine whether demand becomes more elastic in
response to increased choice.
Exploit a policy change in English NHS that mandated
expanded choices for consumers.
Prices are regulated so choice is driven by non-price attributes,
in particular, quality of care.
Not obvious that increased choice will make demand more
responsive to quality.
switching costs; non-rational decisions (e.g. status quo bias);
lack of/poor information
Previous evidence on demand responsiveness to quality.
Luft, Garnick, Mark, Peltzman, Phibbs, Lichtenberg, McPhee,
(1990), Tay (2003), Howard (2005), Sivey (2008).
Gaynor, Propper, Seiler Free to Choose? Page 4 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Questions
What We Do
What We Do
Use individual data on patient choice of hospital for CABG
surgery in the English NHS before and after the reform to
estimate responsiveness of choice to quality (mortality, waiting
time).
Hospital discharge data from the NHS.
Multinomial logit model with heterogeneity.
Risk adjust mortality; instrument for waiting time.
No supply side.
Gaynor, Propper, Seiler Free to Choose? Page 5 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Questions
What We Do
We Find
Patients value lower mortality rates, lower waiting times, less
distance.
Allowing for heterogeneity
No diļ¬€erence in eļ¬€ect of mortality rates on demand pre- and
post-reform on average, but sicker patients more responsive to
quality post-reform.
The eļ¬€ect of waiting time on demand is smaller post reform.
Sicker patients are less responsive to waiting times
post-reform, poorer patients are more responsive.
Hospitals are spatially diļ¬€erentiated. Distance negatively
aļ¬€ects demand and cross-elasticities with respect to quality
fall with distance between hospitals.
Gaynor, Propper, Seiler Free to Choose? Page 6 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
The Reform
CABG Surgery
The Reform
Reforms in English NHS in 2006 designed to promote patient
choice and competition among hospitals.
ā€œChoose and Bookā€: Mandated that patients oļ¬€ered choice of
5 hospitals.
Pre-reform patients referred to hospital with which their local
HA had a contract.
30% of patients aware of choice in 2006; 50% in 2009.
ā€œPbRā€: Hospitals paid ļ¬xed, regulated prices (analogous to
PPS).
Pre-reform local health authorities negotiated contracts with
hospitals (price, volume, waiting time).
Hospitals classiļ¬ed as Foundation Trusts allowed to keep
surpluses. Hospitals designated FTs on performance (ļ¬nancial,
waiting times).
Gaynor, Propper, Seiler Free to Choose? Page 7 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
The Reform
CABG Surgery
The Reform summary
Patients provided with more choices, both via Choose and
Book and end of selective contracting.
Hospitals moved from negotiated price environment to
regulated price environment.
Hospitals have incentives for ļ¬nancial performance.
Gaynor, Propper, Seiler Free to Choose? Page 8 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
The Reform
CABG Surgery
CABG Surgery
Coronary artery bypass graft surgery.
Treatment for coronary artery disease
Frequently performed elective treatment (āˆ¼13K patients per
year).
Risky so mortality rate relevant and observable measure of
quality of care.
Referral
Patients in NHS with coronary artery disease or angina are
referred to a cardiologist.
Referral for CABG surgery typically made by cardiologist
(possibly by GP).
Market
28, 29 hospitals oļ¬€er CABG (out of āˆ¼160).
Market is national (England).
Patients pay nothing.
Gaynor, Propper, Seiler Free to Choose? Page 9 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Data
Inpatient discharge data set for all NHS hospitals (Hospital
Episode Statistics, HES).
All CABG patients treated in NHS hospitals (private providers
not relevant).
Diagnoses, procedures, patient post code, hospital location,
patient characteristics (age, sex, co-morbidities), time between
referral and treatment (waiting time), patient mortality within
30 days of treatment, elective treatment.
Merge area characteristics.
Use elective CABGs (75% of total).
Pre-reform: ļ¬scal years 2003/04, 2004/05.
Post-reform: ļ¬scal years 2006/07, 2007/08.
Gaynor, Propper, Seiler Free to Choose? Page 10 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Descriptive Statistics ā€“ Patients
Standard 10th 90th
Mean Median Deviation Percentile Percentile
Age 65.76 66 55.04 53 76
Index of Multiple 0.14 0.1 0.11 0.04 0.31
Deprivation
Comorbidity Count 5.42 5 2.81 2 9
Capped Comorbidity 4.57 5 1.61 2 6
Count (Cap = 6)
Probability of Informed- 0.53 0.53 0.07 0.45 0.63
ness About Choice
Fraction Male 81.18%
Gaynor, Propper, Seiler Free to Choose? Page 11 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Descriptive Statistics ā€“ Hospitals
Total Admissions Waiting Times
CABGs (Days)
Mean Std Mean Std
2003 502.9 189.4 109.1 32.1
2004 507.5 200.0 100.5 20.7
2005 449.1 170.8 67.8 15.2
2006 425.4 172.7 65.6 17.3
2007 459.9 169.9 64.9 21.4
Gaynor, Propper, Seiler Free to Choose? Page 12 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Descriptes Statistics ā€“ Hospitals Continued
Mortality Rate Adjusted Mortality
CABGs Rate, CABGs
Mean Std Mean Std
2003 1.88 0.82 1.67 1.39
2004 1.93 0.78 1.46 1.45
2005 1.90 0.57 1.19 1.14
2006 1.95 0.79 1.40 1.18
2007 1.51 0.69 0.73 0.90
Gaynor, Propper, Seiler Free to Choose? Page 13 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Descriptive Statistics ā€“ Distance
Standard
Mean Median Deviation 10% 90% 95%
Distance Pre 34.93 22.34 44.97 4.77 71.40 98.15
Post 32.24 22.91 32.94 4.93 70.58 92.36
Fraction of Patients Visiting
Closest Hospital
Pre 68.14
Post 68.67
Gaynor, Propper, Seiler Free to Choose? Page 14 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Patterns in the Data
Are patterns consistent with reforms having an impact?
Do better hospitals have higher market shares after
introduction of choice?
Regress case-mix adjusted hospital mortality rates and hospital
ļ¬xed eļ¬€ects on hospital market shares pre- and post-reform,
for elective and for emergency CABG (placebo test).
Mortality rates are negatively related to market share post-
reform for elective CABG. No signiļ¬cant relationship
pre-reform for elective CABG or at all for emergency CABG.
Gaynor, Propper, Seiler Free to Choose? Page 15 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Mortality Rates and Market Shares ā€“ Elective CABGs
(1) (2) (3) (4)
Dependent variable Elective CABGs Market-share
Time period Pre Post Pre Post
Coeļ¬ƒcient 0.0042 -0.1652** 0.0416 -0.0692*
on Case-Mix Adjusted (0.0552) (0.0622) (0.0267) (0.0321)
Mortality Rate
Hospital Fixed Eļ¬€ects No No Yes Yes
Number of Observations 142 143 142 143
Hospitals 29 29 29 29
Quarters 5 5 5 5
Gaynor, Propper, Seiler Free to Choose? Page 16 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Mortality Rates and Market Shares ā€“ Emergency CABGs
(5) (6) (7) (8)
Dependent variable Emergency CABGs Market-share
Time period Pre Post Pre Post
Coeļ¬ƒcient 0.0488 -0.0667 -0.0373 -0.0127
on Case-Mix Adjusted (0.0531) (0.0744) (0.0379) (0.0466)
Mortality Rate
Hospital Fixed Eļ¬€ects No No Yes Yes
Number of Observations 142 143 142 143
Hospitals 29 29 29 29
Quarters 5 5 5 5
Gaynor, Propper, Seiler Free to Choose? Page 17 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Patterns in the Data 2
Did the mortality rate drop after the introduction of choice?
Yes
Did the mortality rate drop more for patients who bypass the
nearest hospital?
Yes ā€“ consistent with patients exercising more choice.
Gaynor, Propper, Seiler Free to Choose? Page 18 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Descriptive Statistics
Changes in the Expected Mortality Rate
Mortality Rate ā€“ Case-Mix Adjusted
All Patients 1.471 0.748 -0.723
Patients Visiting Nearest Hospital 1.352 0.809 -0.543
Patients Not Visiting Nearest Hosp. 1.716 0.606 -1.110
Gaynor, Propper, Seiler Free to Choose? Page 19 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Hospital Choice
Correlations
Modelling Approach
2 parts to econometric model
Hospital choice as a function of hospital
characteristics/dimensions of service (quality, waiting times,
distance)
Use hospital production function for quality of clinical care to
overcome endogeneity of mortality rates
Focus is demand model ā€“ pin down how sensitive hospital
choice decisions are to quality of care
Allow for patient level heterogeneity and unobserved
heterogeneity at hospital level
Agency
Physician plays a major role in hospital choice ā€“ canā€™t
separately identify patient and physician preferences
Not an issue for identifying impact of reform on hospital choice
Physicians in NHS salaried ā€“ no ļ¬nancial incentive wrt referrals
Gaynor, Propper, Seiler Free to Choose? Page 20 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Hospital Choice
Correlations
Choice Model
Patient i chooses hospital j to visit in time period t which
provides the maximum utility according to:
Vijt = Ī²w,itWjt + Ī²z,itZjt + f (Dij) + Ī¾jt + Īµijt
where:
W is waiting time, Z is the hospitalā€™s mortality rate, D is the
distance from patient i to hospital j.
Ī¾jt is unobserved hospital quality, Īµijt is a random iid shock
distributed Type I Extreme Value.
We allow for heterogeneity across patients in preferences for
observables and unobservables.
Gaynor, Propper, Seiler Free to Choose? Page 21 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Hospital Choice
Correlations
Choice Model, contā€™d.
Allow impacts of quality of care and waiting times to diļ¬€er
across patients and before and after the reform
Gaynor, Propper, Seiler Free to Choose? Page 22 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Hospital Choice
Correlations
Correlation
May be correlations between waiting times or mortality rates
and unobserved hospital quality.
Unobservably better hospitals may attract more patients and
thus have longer waiting times.
Unobservably better hospitals may attract sicker patients and
thus have higher mortality rates.
Deal with both - assume distance (dij) is uncorrelated with
unobserved hospital quality (Ī¾j), i.e. patients donā€™t choose
where to live based on hospitalsā€™ quality of care for CABG
surgery.
Gaynor, Propper, Seiler Free to Choose? Page 23 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
First Step Estimates
We ļ¬nd:
Sicker patients are sensitive to hospital mortality rates and
more sensitive after choice reform.
ā€œLow incomeā€ patients more sensitive to waiting times after
choice reform.
ā€œInformedā€ patients more sensitive to waiting times.
Distance matters.
Gaynor, Propper, Seiler Free to Choose? Page 24 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
First Step Estimates
Coeļ¬ƒcient Stand. Error
Income Waiting Pre 0.01 0.68
Deprivation Times Post -3.85 0.65 **
Index Mortality Pre 0.12 0.86
Rate Post -0.02 1.13
Co- Waiting Pre 5.67 0.43 **
Morbidity Times Post 4.10 0.58 **
Count Mortality Pre -10.11 0.56 **
Rate Post -13.18 0.94 **
Patient Waiting Pre 1.25 0.66 *
Informedness Times Post -4.41 0.65 **
Mortality Pre 5.17 0.83 **
Rate Post 0.01 1.06
Unobserved Waiting Pre -0.22 75.36
Preference Times Post -0.26 76.70
Heterogeneity Mortality Pre 35.02 0.87 **
Rate Post 39.04 1.81 **
Gaynor, Propper, Seiler Free to Choose? Page 25 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
2nd Step Estimates ā€“ Average Eļ¬€ects
Patients more responsive to mortality rates post-reform: large
impact.
Waiting times not signiļ¬cant either pre- or post-reform.
Gaynor, Propper, Seiler Free to Choose? Page 26 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
2nd Step Estimates ā€“ Av Eļ¬€ects (cont)
Baseline Sensitivity
Speciļ¬cation Check
Average Eļ¬€ect Coeļ¬€. S.E. Coeļ¬€. S.E.
Waiting Pre -4.24 3.15 0.43 4.09
Times Post 6.25 4.74 13.45 7.53
Quality Pre -4.85 3.70 -1.63 3.81
Post -12.40 4.00** -11.39 3.96**
Hospital Fixed Constant Fixed Eļ¬€ects Separate Fixed Eļ¬€ects
Eļ¬€ects Pre- and Post-Reform Pre- and Post-Reform
Gaynor, Propper, Seiler Free to Choose? Page 27 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
Elasticities
Calculate impact of a 1 standard deviation change in mortality
rate.
Calculate patient and hospital level elasticities using the
parameter estimates.
Patients
Large increases in responsiveness, elasticities small.
Hospitals
Large increases in responsiveness.
Elasticities small (but larger than patient).
Gaynor, Propper, Seiler Free to Choose? Page 28 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
Patientā€“Level Elasticities of Demand
Impact on Patientā€™s Choice Probability
From 1 S.D. Shift in Adjusted Mortality Elasticity
Average Patient -2.69 -0.021
Pre-Reform Lower Income -2.63 -0.021
Higher Comorb -8.30 -0.066
More Informed 0.18 0.001
Average Patient -7.08 -0.056
Post-Reform Lower Income -7.09 -0.056
Higher Comorb -14.40 -0.114
More Informed -7.08 -0.056
Gaynor, Propper, Seiler Free to Choose? Page 29 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
Hospital Elasticities
1-S.D. Shift Mean S.D. 25th Perc. Median 75th Perc.
Pre-Reform -0.36 5.11 -1.73 0.11 0.56
Post-Reform -4.83 4.73 -5.66 -3.14 -2.34
Change -5.38 5.81 -6.25 -2.88 -2.28
Elasticities Mean S.D. 25th Perc. Median 75th Perc.
Pre-Reform 0.02 0.16 -0.03 0.00 0.01
Post-Reform -0.12 0.07 -0.16 -0.10 -0.05
Change -0.14 0.19 -0.15 -0.07 -0.05
Gaynor, Propper, Seiler Free to Choose? Page 30 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
Policy Evaluations
Impact of choice on patient survival.
How many more people would have died absent the reform?
If patients in the post-reform period were subject to pre-reform
constraints and chose with pre-reform parameters.
12 more people would have died absent the reform.
Change in patient welfare
What is impact on utility of freedom of choice?
Compare utility post-reform patients received with utility they
would have received if theyā€™d chosen with ā€œrestrictedā€ pre-
reform choice parameters.
Freeing choice led to 7.68% increase in patient welfare.
Supply Side
Regress change in adjusted mortality on change in demand
elasticity with respect to quality.
Large response of mortality rate to elasticity ā€“ consistent with
a supply side response.
Gaynor, Propper, Seiler Free to Choose? Page 31 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
Supply Side Response
Dependent Variable Change in Case-Mix
Adjusted Mortality Rate
Change in the Elasticity -0.1296***
of Demand with Respect (0.0209)
to the Mortality Rate
Observations 27
Gaynor, Propper, Seiler Free to Choose? Page 32 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
1st-Step Estimates ā€“ Heterogeneity
2nd-Step Estimates
Spatial Diļ¬€erentiation
Calculate cross-elasticities with respect to mortality rate for every pair of
hospitals (both directions), graphed against distance between the two
hospitals.
Ā 
Ā 
Ā 
Ā 
Ā 
Ā 
-6-4-202
log_elast
1 2 3 4 5 6
log_dist
Hospitals nearby are close substitutes, little competition with far away
hospitals.
Gaynor, Propper, Seiler Free to Choose? Page 33 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Summary and Conclusions
Test one of basic premises of competitive models ā€“ that
demand elasticity increases with choice.
Find that it does and there is substantial heterogeneity in
consumer response.
More severely ill patients become more sensitive to quality of
care post-reform.
No evidence that lower income patients chose lower quality
hospitals post reform.
Implies that the NHS reforms had an impact on demand, a
necessary condition for competition.
Sheds some light on the results from previous studies.
Choice and competition can play an important role in health
care.
Gaynor, Propper, Seiler Free to Choose? Page 34 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Thank you
Gaynor, Propper, Seiler Free to Choose? Page 35 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Choice Model
Patient i chooses hospital j to visit in time period t which
provides the maximum utility according to:
Vijt = Ī²w,itWjt + Ī²z,itZjt + f (Dij) + Ī¾jt + Īµijt
where:
W is waiting time, Z is the hospitalā€™s mortality rate, D is the
distance from patient i to hospital j.
Ī¾jt is unobserved hospital quality, Īµijt is a random iid shock
distributed Type I Extreme Value.
We allow for heterogeneity across patients in preferences for
observables and unobservables.
Gaynor, Propper, Seiler Free to Choose? Page 36 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Choice Model, contā€™d.
Allow impacts of quality of care and waiting times to diļ¬€er
across patients and before and after the reform
Ī²z,it = [Ī²z,0 + Ī²z,0Xi + Ļƒz,0vz,i] Ā· 1(t = 0)
+[Ī²z,1 + Ī²z,1Xit + Ļƒz,1vz,i] Ā· 1(t = 1).
Ī²w,it = [Ī²w,0 + Ī²w,0Xi + Ļƒw,0vw,i] Ā· 1(t = 0)
+[Ī²w,1 + Ī²w,1Xi + Ļƒw,1vw,i] Ā· 1(t = 1)
where (t = 0) is pre-reform time period, (t = 1) is
post-reform, Ī²z,t is average eļ¬€ect across consumers in period
t, Xi is observable patient demographics, Ī²z,t captures
diļ¬€erences from the average eļ¬€ect across consumers, Ļƒz,t
captures unobserved heterogeneity.Gaynor, Propper, Seiler Free to Choose? Page 37 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Waiting Times
Hospitals with higher unobserved quality will have greater
demand, and therefore higher waiting times.
Could use IV or control for unobserved heterogeneity via ļ¬xed
eļ¬€ects to absorb the variation in Ī¾jt.
No obvious good instrument so we use hospital-quarter ļ¬xed
eļ¬€ects i.e. time varying ļ¬xed eļ¬€ects.
Cost to this: have to use two-step approach to identify
average eļ¬€ects (almost 300 ļ¬xed eļ¬€ects).
Gaynor, Propper, Seiler Free to Choose? Page 38 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Production Function for Clinical Quality of Care
Use hospitalā€™s mortality rate for CABG patients as measure of
the quality of care.
Use the production function to deliver an appropriate measure
of quality of care for demand model.
Linear probability model of mortality:
M = JTĻˆ + Hobs
Ī³obs + Hunobs
Ī³unobs + Ī·
where M is mortality, JT is a matrix of hospital-time period
dummy variables, Hobs is a matrix of patient characteristics
that capture observable health status. Hunobs is unobserved
health status.
Gaynor, Propper, Seiler Free to Choose? Page 39 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Correlation
Issue - better hospitals attract sicker patients leading to a
correlation with the error.
Very similar to problem of hospital mortality rates being
ā€œcontaminatedā€ by diļ¬€erences in patient case-mix.
Implies need to control for patientā€™s health status.
Follow Gowrisankaran and Town (1999): instrument for the
hospital dummies using distance.
Use distance and dummies for closest hospital: 2 Ɨ as many
instruments as hospital dummies.
Estimate as linear probability model.
Use the IV estimates of Ė†Ļˆjt as our risk-adjusted measure of the
hospital mortality rate.
Gaynor, Propper, Seiler Free to Choose? Page 40 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
First Step contā€™d.
Coeļ¬ƒcient S. E.
Distance Linear -14.86 0.21 **
Square 4.91 0.11 **
Cube -0.57 0.02 **
Closest Dummy 1.07 0.02 **
Closest ā€Plus 10ā€ Dummy -0.01 0.00 *
Closest ā€Plus 20ā€ Dummy 0.01 0.05
Gaynor, Propper, Seiler Free to Choose? Page 41 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Demand with Heterogeneity and Hospital Fixed Eļ¬€ects
Time Period Pre-Reform Post-Reform
Waiting Time -0.022 -0.020
(0.014) (0.015)
Mortality Rate (Adjusted) -0.003 -0.007
(0.004) (0.006)
Error From First Stage 0.027*
(Control Function) (0.014)
Waiting Time 0.028*** 0.025***
* Comorbidity Count (0.002) (0.003)
Mortality Rate (Adjusted) -0.021*** -0.060***
* Comorbidity Count (0.002) (0.004)
Waiting Time -0.040 -0.336***
* IMD Index (0.033) (0.044)
Mortality Rate (Adjusted) 0.035 0.060
* IMD Index (0.034) (0.049)
Observations 51,793
Gaynor, Propper, Seiler Free to Choose? Page 42 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
IV Mortality Rate Model
In order to obtain adjusted mortality rates we run a linear
probability model, regressing a dummy for death on a set of
quarter-speciļ¬c hospital dummies. The hospital dummies are
stacked in a block-diagonal matrix, each block representing one
quarter out of 20 quarter for the time period 2001 to 2005. The
case-mix is restricted to enter in the same way in all quarters.
Speciļ¬cally, the data are arranged as follows:
X =
ļ£®
ļ£Æ
ļ£Æ
ļ£Æ
ļ£°
X1 CM1
X2 CM2
...
...
X20 CM20
ļ£¹
ļ£ŗ
ļ£ŗ
ļ£ŗ
ļ£»
Gaynor, Propper, Seiler Free to Choose? Page 43 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
IV Mortality Rate Model Contā€™d.
Where CMt denotes a matrix with various variables capturing the
health status of patients within a particular quarter t. All elements
in the matrix other then the matrices X1 to X20 and CM1 to
CM20 are equal to zero. The block-diagonal elements are given by:
Xt =
ļ£®
ļ£Æ
ļ£°
xt
11 Ā· Ā· Ā· xt
1kt
...
...
...
xt
nt1 Ā· Ā· Ā· xt
ntkt
ļ£¹
ļ£ŗ
ļ£»
Where nt denotes the number of patients in a particular quarter t,
i.e. the number of observations in the data. kt denotes the number
of hospital dummies in each quarter. This number varies across
quarters because of hospital entry, exit and mergers.
Gaynor, Propper, Seiler Free to Choose? Page 44 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
IV Mortality Rate Model Contā€™d.
The matrix of instruments is arranged in a similar fashion:
Z =
ļ£®
ļ£Æ
ļ£Æ
ļ£Æ
ļ£°
Z1 CM1
Z2 CM2
...
...
Z20 CM20
ļ£¹
ļ£ŗ
ļ£ŗ
ļ£ŗ
ļ£»
with
Zt =
ļ£®
ļ£Æ
ļ£°
zt
11 Ā· Ā· Ā· zt
1lt
...
...
...
zt
nt1 Ā· Ā· Ā· zt
ntlt
ļ£¹
ļ£ŗ
ļ£»
Gaynor, Propper, Seiler Free to Choose? Page 45 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
IV Mortality Rate Model Contā€™d.
Where nt denotes the number of patients in a particular quarter t
(as in the X-matrix above). lt denotes the number of quarter-
speciļ¬c instruments. In general we need the condition lt > kt āˆ’ 1
to be fulļ¬lled in all quarters (We do not need an instrument for the
constant in each quarter, i.e. the average quarterly death rate over
all hospitals). In practice we use the distance to each hospital
available in the quarter and a dummy for whether this is the
closest hospital for the individual patient as instruments. This
yields lt = 2 āˆ— kt instruments for each quarter.
Gaynor, Propper, Seiler Free to Choose? Page 46 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Changes in Survival Probability due to the Reform
Change in Survival when Choices Post-Reform -12.17
are Made with Pre-Reform Parameters
Post-Reform Admissions 20338
(5 Quarters) Deaths 393
Mortality Rate 1.93
Recomputed Mortality Rate
1.87
Gaynor, Propper, Seiler Free to Choose? Page 47 out of 48
Introduction
Institutional Facts
Data
The Model
Results
Summary and Conclusions
Hospital Selection Based on Severity
Adjusted Adjusted
Dependent Variable Mortality Rate Mortality Rate
Co-morbidity Count -0.220** -0.180**
(0.006) (0.006)
Quarter Fixed Eļ¬€ects No Yes
(Flexible Time Trend)
Number of Observations 32,715 32,715
Gaynor, Propper, Seiler Free to Choose? Page 48 out of 48

More Related Content

What's hot

Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
Ā 
Iggbo_Oncology_whitepaper_v2
Iggbo_Oncology_whitepaper_v2Iggbo_Oncology_whitepaper_v2
Iggbo_Oncology_whitepaper_v2Brad Seybert
Ā 
ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021
ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021
ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021Starttech Ventures
Ā 
SVMPharma Real World Evidence ā€“ Why NHS must embrace Real World Data
SVMPharma Real World Evidence ā€“ Why NHS must embrace Real World DataSVMPharma Real World Evidence ā€“ Why NHS must embrace Real World Data
SVMPharma Real World Evidence ā€“ Why NHS must embrace Real World DataSVMPharma Limited
Ā 
Movers & shakers interview with vivek trikha head diagnostics onc quest ...
Movers & shakers interview with vivek trikha head  diagnostics onc quest ...Movers & shakers interview with vivek trikha head  diagnostics onc quest ...
Movers & shakers interview with vivek trikha head diagnostics onc quest ...oncquest
Ā 
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Office of Health Economics
Ā 
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...Andrew Aijian
Ā 
January 2017 Corporate Presentation
January 2017 Corporate PresentationJanuary 2017 Corporate Presentation
January 2017 Corporate Presentationoncolyticsinc
Ā 
A CTTI Survey of Current Monitoring Practices
A CTTI Survey of Current Monitoring PracticesA CTTI Survey of Current Monitoring Practices
A CTTI Survey of Current Monitoring PracticesTarget Health, Inc.
Ā 
Understanding Different Stakeholder Requirements Throughout Commercialization
Understanding Different Stakeholder Requirements Throughout CommercializationUnderstanding Different Stakeholder Requirements Throughout Commercialization
Understanding Different Stakeholder Requirements Throughout CommercializationPAREXEL International
Ā 
Leveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical TrialsLeveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical TrialsPAREXEL International
Ā 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Andrew Aijian
Ā 
Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...
Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...
Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...PAREXEL International
Ā 
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Andrew Aijian
Ā 
Stem cells: Information environment
Stem cells: Information environmentStem cells: Information environment
Stem cells: Information environmentArete-Zoe, LLC
Ā 
Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...PAREXEL International
Ā 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Life Sciences Network marcus evans
Ā 
Austria 1652011
Austria 1652011Austria 1652011
Austria 1652011Sherif Kamal
Ā 

What's hot (20)

Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Ā 
Iggbo_Oncology_whitepaper_v2
Iggbo_Oncology_whitepaper_v2Iggbo_Oncology_whitepaper_v2
Iggbo_Oncology_whitepaper_v2
Ā 
ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021
ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021
ĪĪ¹ĪŗĻŒĪ»Ī±ĪæĻ‚ Ī¤ĻƒĪæĻĪ»ĪæĻ‚, MedTech Conference 2021
Ā 
SVMPharma Real World Evidence ā€“ Why NHS must embrace Real World Data
SVMPharma Real World Evidence ā€“ Why NHS must embrace Real World DataSVMPharma Real World Evidence ā€“ Why NHS must embrace Real World Data
SVMPharma Real World Evidence ā€“ Why NHS must embrace Real World Data
Ā 
Movers & shakers interview with vivek trikha head diagnostics onc quest ...
Movers & shakers interview with vivek trikha head  diagnostics onc quest ...Movers & shakers interview with vivek trikha head  diagnostics onc quest ...
Movers & shakers interview with vivek trikha head diagnostics onc quest ...
Ā 
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Ā 
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
Ā 
Trends in Early Development
Trends in Early DevelopmentTrends in Early Development
Trends in Early Development
Ā 
January 2017 Corporate Presentation
January 2017 Corporate PresentationJanuary 2017 Corporate Presentation
January 2017 Corporate Presentation
Ā 
A CTTI Survey of Current Monitoring Practices
A CTTI Survey of Current Monitoring PracticesA CTTI Survey of Current Monitoring Practices
A CTTI Survey of Current Monitoring Practices
Ā 
Understanding Different Stakeholder Requirements Throughout Commercialization
Understanding Different Stakeholder Requirements Throughout CommercializationUnderstanding Different Stakeholder Requirements Throughout Commercialization
Understanding Different Stakeholder Requirements Throughout Commercialization
Ā 
Leveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical TrialsLeveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical Trials
Ā 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Ā 
Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...
Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...
Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...
Ā 
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Ā 
Stem cells: Information environment
Stem cells: Information environmentStem cells: Information environment
Stem cells: Information environment
Ā 
Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...
Ā 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Ā 
Austria 1652011
Austria 1652011Austria 1652011
Austria 1652011
Ā 
NeoGenomics, Inc. Company Overview Presentation 2013_10_01
NeoGenomics, Inc. Company Overview Presentation 2013_10_01NeoGenomics, Inc. Company Overview Presentation 2013_10_01
NeoGenomics, Inc. Company Overview Presentation 2013_10_01
Ā 

Viewers also liked

Estimating demand response potential in urban condominiums of Japan 10.12.12
Estimating demand response potential in urban condominiums of Japan 10.12.12Estimating demand response potential in urban condominiums of Japan 10.12.12
Estimating demand response potential in urban condominiums of Japan 10.12.12Reina Kohtake
Ā 
PG&E Demand Response Programs
PG&E Demand Response ProgramsPG&E Demand Response Programs
PG&E Demand Response Programsmichaeljmack
Ā 
Automated Demand Response Strategies for Market Participation and Grid Manage...
Automated Demand Response Strategies for Market Participation and Grid Manage...Automated Demand Response Strategies for Market Participation and Grid Manage...
Automated Demand Response Strategies for Market Participation and Grid Manage...IEA DSM Implementing Agreement (IA)
Ā 
Doe Smart Grid
Doe   Smart GridDoe   Smart Grid
Doe Smart GridWDMcCall
Ā 
Integration of Demand Side Management, Distributed Generation, Renewable Ener...
Integration of Demand Side Management, Distributed Generation, Renewable Ener...Integration of Demand Side Management, Distributed Generation, Renewable Ener...
Integration of Demand Side Management, Distributed Generation, Renewable Ener...IEA DSM Implementing Agreement (IA)
Ā 
Electric Vehicles and Demand Response Opportunty in California, 2010-2030
Electric Vehicles and Demand Response Opportunty in California, 2010-2030Electric Vehicles and Demand Response Opportunty in California, 2010-2030
Electric Vehicles and Demand Response Opportunty in California, 2010-2030Brian Moss
Ā 
Autonomous Demand Response using Stochastic Differential Games
Autonomous Demand Response using Stochastic Differential GamesAutonomous Demand Response using Stochastic Differential Games
Autonomous Demand Response using Stochastic Differential GamesNajmeh Forouzandehmehr
Ā 
The Future of Residential Demand Response: BGE's Integration of Demand Respon...
The Future of Residential Demand Response: BGE's Integration of Demand Respon...The Future of Residential Demand Response: BGE's Integration of Demand Respon...
The Future of Residential Demand Response: BGE's Integration of Demand Respon...E Source Companies, LLC
Ā 
Converting Demand Side Operation in to an Accurate Tool for the Transmission ...
Converting Demand Side Operation in to an Accurate Tool for the Transmission ...Converting Demand Side Operation in to an Accurate Tool for the Transmission ...
Converting Demand Side Operation in to an Accurate Tool for the Transmission ...IEA DSM Implementing Agreement (IA)
Ā 
Efficiency & Demand Response Programs service from E Source
Efficiency & Demand Response Programs service from E SourceEfficiency & Demand Response Programs service from E Source
Efficiency & Demand Response Programs service from E SourceE Source Companies, LLC
Ā 
Demand Response in Ireland
Demand Response in IrelandDemand Response in Ireland
Demand Response in IrelandKiwiPower1
Ā 
Demand Response: The Key to a Competitive Facility
Demand Response: The Key to a Competitive FacilityDemand Response: The Key to a Competitive Facility
Demand Response: The Key to a Competitive FacilitySchneider Electric
Ā 
Demand Response workshop - Powering Sydney
Demand Response workshop - Powering SydneyDemand Response workshop - Powering Sydney
Demand Response workshop - Powering SydneyTransGrid AU
Ā 
How does Demand Response reduce electricity use?
How does Demand Response reduce electricity use?How does Demand Response reduce electricity use?
How does Demand Response reduce electricity use?Environmental Defense Fund
Ā 
From Load Forecasting to Demand Response - A Web of Things Use Case
From Load Forecasting to Demand Response  - A Web of Things Use CaseFrom Load Forecasting to Demand Response  - A Web of Things Use Case
From Load Forecasting to Demand Response - A Web of Things Use CaseTill Riedel
Ā 
Business Ecosystem View on Demand Response
Business Ecosystem View on Demand ResponseBusiness Ecosystem View on Demand Response
Business Ecosystem View on Demand ResponseCLEEN_Ltd
Ā 
USA Activities on DSM (Demand Response & Energy Efficiency)
USA Activities on DSM (Demand Response & Energy Efficiency)USA Activities on DSM (Demand Response & Energy Efficiency)
USA Activities on DSM (Demand Response & Energy Efficiency)IEA DSM Implementing Agreement (IA)
Ā 

Viewers also liked (18)

Estimating demand response potential in urban condominiums of Japan 10.12.12
Estimating demand response potential in urban condominiums of Japan 10.12.12Estimating demand response potential in urban condominiums of Japan 10.12.12
Estimating demand response potential in urban condominiums of Japan 10.12.12
Ā 
PG&E Demand Response Programs
PG&E Demand Response ProgramsPG&E Demand Response Programs
PG&E Demand Response Programs
Ā 
Automated Demand Response Strategies for Market Participation and Grid Manage...
Automated Demand Response Strategies for Market Participation and Grid Manage...Automated Demand Response Strategies for Market Participation and Grid Manage...
Automated Demand Response Strategies for Market Participation and Grid Manage...
Ā 
Doe Smart Grid
Doe   Smart GridDoe   Smart Grid
Doe Smart Grid
Ā 
Integration of Demand Side Management, Distributed Generation, Renewable Ener...
Integration of Demand Side Management, Distributed Generation, Renewable Ener...Integration of Demand Side Management, Distributed Generation, Renewable Ener...
Integration of Demand Side Management, Distributed Generation, Renewable Ener...
Ā 
Electric Vehicles and Demand Response Opportunty in California, 2010-2030
Electric Vehicles and Demand Response Opportunty in California, 2010-2030Electric Vehicles and Demand Response Opportunty in California, 2010-2030
Electric Vehicles and Demand Response Opportunty in California, 2010-2030
Ā 
Autonomous Demand Response using Stochastic Differential Games
Autonomous Demand Response using Stochastic Differential GamesAutonomous Demand Response using Stochastic Differential Games
Autonomous Demand Response using Stochastic Differential Games
Ā 
The Future of Residential Demand Response: BGE's Integration of Demand Respon...
The Future of Residential Demand Response: BGE's Integration of Demand Respon...The Future of Residential Demand Response: BGE's Integration of Demand Respon...
The Future of Residential Demand Response: BGE's Integration of Demand Respon...
Ā 
Converting Demand Side Operation in to an Accurate Tool for the Transmission ...
Converting Demand Side Operation in to an Accurate Tool for the Transmission ...Converting Demand Side Operation in to an Accurate Tool for the Transmission ...
Converting Demand Side Operation in to an Accurate Tool for the Transmission ...
Ā 
Efficiency & Demand Response Programs service from E Source
Efficiency & Demand Response Programs service from E SourceEfficiency & Demand Response Programs service from E Source
Efficiency & Demand Response Programs service from E Source
Ā 
Demand Response in Ireland
Demand Response in IrelandDemand Response in Ireland
Demand Response in Ireland
Ā 
Demand Response: The Key to a Competitive Facility
Demand Response: The Key to a Competitive FacilityDemand Response: The Key to a Competitive Facility
Demand Response: The Key to a Competitive Facility
Ā 
Demand Response workshop - Powering Sydney
Demand Response workshop - Powering SydneyDemand Response workshop - Powering Sydney
Demand Response workshop - Powering Sydney
Ā 
KEPCO's Demand Side Management Programs
KEPCO's Demand Side Management ProgramsKEPCO's Demand Side Management Programs
KEPCO's Demand Side Management Programs
Ā 
How does Demand Response reduce electricity use?
How does Demand Response reduce electricity use?How does Demand Response reduce electricity use?
How does Demand Response reduce electricity use?
Ā 
From Load Forecasting to Demand Response - A Web of Things Use Case
From Load Forecasting to Demand Response  - A Web of Things Use CaseFrom Load Forecasting to Demand Response  - A Web of Things Use Case
From Load Forecasting to Demand Response - A Web of Things Use Case
Ā 
Business Ecosystem View on Demand Response
Business Ecosystem View on Demand ResponseBusiness Ecosystem View on Demand Response
Business Ecosystem View on Demand Response
Ā 
USA Activities on DSM (Demand Response & Energy Efficiency)
USA Activities on DSM (Demand Response & Energy Efficiency)USA Activities on DSM (Demand Response & Energy Efficiency)
USA Activities on DSM (Demand Response & Energy Efficiency)
Ā 

Similar to Carol Propper: Reform and demand response in the NHS

Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
Ā 
Integrated ACO selected for the NAACOS Innovation Showcase
Integrated ACO selected for the NAACOS Innovation ShowcaseIntegrated ACO selected for the NAACOS Innovation Showcase
Integrated ACO selected for the NAACOS Innovation ShowcaseEric Weaver
Ā 
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...MedStatix, LLC
Ā 
Rising Importance of Health Economics & Outcomes Research
Rising Importance of Health Economics & Outcomes ResearchRising Importance of Health Economics & Outcomes Research
Rising Importance of Health Economics & Outcomes ResearchCitiusTech
Ā 
Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6
Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6
Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6Health Catalyst
Ā 
BRG Albany HFMA 4.23.15
BRG Albany HFMA 4.23.15BRG Albany HFMA 4.23.15
BRG Albany HFMA 4.23.15Mark Driscoll
Ā 
white-paper-innovation-clinical-trials
white-paper-innovation-clinical-trialswhite-paper-innovation-clinical-trials
white-paper-innovation-clinical-trialsUlrich Neumann, FRSA
Ā 
Establishing Performance Standards
Establishing Performance StandardsEstablishing Performance Standards
Establishing Performance StandardsHaythamHagrass
Ā 
Dr Jennifer Dixon: Competition between providers
Dr Jennifer Dixon: Competition between providersDr Jennifer Dixon: Competition between providers
Dr Jennifer Dixon: Competition between providersNuffield Trust
Ā 
Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...
Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...
Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...European School of Oncology
Ā 
SAPC north 2010 - provider incentives for influenza immunisation
SAPC north 2010 - provider incentives for influenza immunisationSAPC north 2010 - provider incentives for influenza immunisation
SAPC north 2010 - provider incentives for influenza immunisationEvangelos Kontopantelis
Ā 
OrHIMA Meaningful Use Stage 2 Presentation
OrHIMA Meaningful Use Stage 2 PresentationOrHIMA Meaningful Use Stage 2 Presentation
OrHIMA Meaningful Use Stage 2 PresentationBrian Ahier
Ā 
What can we learn from oncologists? A survey of molecular testing patterns
What can we learn from oncologists? A survey of molecular testing patternsWhat can we learn from oncologists? A survey of molecular testing patterns
What can we learn from oncologists? A survey of molecular testing patternsThermo Fisher Scientific
Ā 
Hugh Gravelle: The impact of care quality on patient choice
Hugh Gravelle: The impact of care quality on patient choiceHugh Gravelle: The impact of care quality on patient choice
Hugh Gravelle: The impact of care quality on patient choiceNuffield Trust
Ā 
Leapee4
Leapee4Leapee4
Leapee4ellenemcc
Ā 
MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...
MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...
MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...Frank Fortin
Ā 
John Appleby - Competition in the NHS: Good or bad (or something else)?
John Appleby - Competition in the NHS: Good or bad (or something else)?John Appleby - Competition in the NHS: Good or bad (or something else)?
John Appleby - Competition in the NHS: Good or bad (or something else)?The King's Fund
Ā 
Diagnostics Market Disruption HIDA final
Diagnostics Market Disruption HIDA finalDiagnostics Market Disruption HIDA final
Diagnostics Market Disruption HIDA finalHidee Cyd
Ā 

Similar to Carol Propper: Reform and demand response in the NHS (20)

Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Ā 
Integrated ACO selected for the NAACOS Innovation Showcase
Integrated ACO selected for the NAACOS Innovation ShowcaseIntegrated ACO selected for the NAACOS Innovation Showcase
Integrated ACO selected for the NAACOS Innovation Showcase
Ā 
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
Ā 
Rising Importance of Health Economics & Outcomes Research
Rising Importance of Health Economics & Outcomes ResearchRising Importance of Health Economics & Outcomes Research
Rising Importance of Health Economics & Outcomes Research
Ā 
Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6
Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6
Making Healthcare Waste Reduction and Patient Safety Actionable - HAS Session 6
Ā 
BRG Albany HFMA 4.23.15
BRG Albany HFMA 4.23.15BRG Albany HFMA 4.23.15
BRG Albany HFMA 4.23.15
Ā 
white-paper-innovation-clinical-trials
white-paper-innovation-clinical-trialswhite-paper-innovation-clinical-trials
white-paper-innovation-clinical-trials
Ā 
Establishing Performance Standards
Establishing Performance StandardsEstablishing Performance Standards
Establishing Performance Standards
Ā 
Dr Jennifer Dixon: Competition between providers
Dr Jennifer Dixon: Competition between providersDr Jennifer Dixon: Competition between providers
Dr Jennifer Dixon: Competition between providers
Ā 
Gaynor.slides.10.22.10
Gaynor.slides.10.22.10Gaynor.slides.10.22.10
Gaynor.slides.10.22.10
Ā 
Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...
Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...
Gene Profiling in Clinical Oncology - Slide 9 - F. AndrƩ - Genomic evaluation...
Ā 
SAPC north 2010 - provider incentives for influenza immunisation
SAPC north 2010 - provider incentives for influenza immunisationSAPC north 2010 - provider incentives for influenza immunisation
SAPC north 2010 - provider incentives for influenza immunisation
Ā 
OrHIMA Meaningful Use Stage 2 Presentation
OrHIMA Meaningful Use Stage 2 PresentationOrHIMA Meaningful Use Stage 2 Presentation
OrHIMA Meaningful Use Stage 2 Presentation
Ā 
What can we learn from oncologists? A survey of molecular testing patterns
What can we learn from oncologists? A survey of molecular testing patternsWhat can we learn from oncologists? A survey of molecular testing patterns
What can we learn from oncologists? A survey of molecular testing patterns
Ā 
Hugh Gravelle: The impact of care quality on patient choice
Hugh Gravelle: The impact of care quality on patient choiceHugh Gravelle: The impact of care quality on patient choice
Hugh Gravelle: The impact of care quality on patient choice
Ā 
Leapee4
Leapee4Leapee4
Leapee4
Ā 
Cgix
CgixCgix
Cgix
Ā 
MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...
MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...
MMS State of the State Conference: Elliott Fisher - Rethinking Health Care - ...
Ā 
John Appleby - Competition in the NHS: Good or bad (or something else)?
John Appleby - Competition in the NHS: Good or bad (or something else)?John Appleby - Competition in the NHS: Good or bad (or something else)?
John Appleby - Competition in the NHS: Good or bad (or something else)?
Ā 
Diagnostics Market Disruption HIDA final
Diagnostics Market Disruption HIDA finalDiagnostics Market Disruption HIDA final
Diagnostics Market Disruption HIDA final
Ā 

More from Nuffield Trust

Transforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement EventTransforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement EventNuffield Trust
Ā 
13 reasons to spend more on health and social care
13 reasons to spend more on health and social care 13 reasons to spend more on health and social care
13 reasons to spend more on health and social care Nuffield Trust
Ā 
Energising your workforce in the face of adversity
Energising your workforce in the face of adversityEnergising your workforce in the face of adversity
Energising your workforce in the face of adversityNuffield Trust
Ā 
Shifting the balance of care: great expectations
Shifting the balance of care: great expectations Shifting the balance of care: great expectations
Shifting the balance of care: great expectations Nuffield Trust
Ā 
Automation, Employment, and Health Care
Automation, Employment, and Health Care Automation, Employment, and Health Care
Automation, Employment, and Health Care Nuffield Trust
Ā 
Public perspectives on the NHS and social care
Public perspectives on the NHS and social carePublic perspectives on the NHS and social care
Public perspectives on the NHS and social careNuffield Trust
Ā 
Evaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeEvaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeNuffield Trust
Ā 
Ensuring success for new models of care
Ensuring success for new models of careEnsuring success for new models of care
Ensuring success for new models of careNuffield Trust
Ā 
Effectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHSEffectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHSNuffield Trust
Ā 
Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...Nuffield Trust
Ā 
Local and national uses of data
Local and national uses of dataLocal and national uses of data
Local and national uses of dataNuffield Trust
Ā 
Applied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillanceApplied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillanceNuffield Trust
Ā 
Engaging with data
Engaging with dataEngaging with data
Engaging with dataNuffield Trust
Ā 
Evaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics UnitEvaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics UnitNuffield Trust
Ā 
Learning from the Care Quality Commission
Learning from the Care Quality CommissionLearning from the Care Quality Commission
Learning from the Care Quality CommissionNuffield Trust
Ā 
Real-time monitoring and the data trap
Real-time monitoring and the data trapReal-time monitoring and the data trap
Real-time monitoring and the data trapNuffield Trust
Ā 
Monitoring quality of care: making the most of data
Monitoring quality of care: making the most of dataMonitoring quality of care: making the most of data
Monitoring quality of care: making the most of dataNuffield Trust
Ā 
Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...Nuffield Trust
Ā 
Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...Nuffield Trust
Ā 
New Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessonsNew Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessonsNuffield Trust
Ā 

More from Nuffield Trust (20)

Transforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement EventTransforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement Event
Ā 
13 reasons to spend more on health and social care
13 reasons to spend more on health and social care 13 reasons to spend more on health and social care
13 reasons to spend more on health and social care
Ā 
Energising your workforce in the face of adversity
Energising your workforce in the face of adversityEnergising your workforce in the face of adversity
Energising your workforce in the face of adversity
Ā 
Shifting the balance of care: great expectations
Shifting the balance of care: great expectations Shifting the balance of care: great expectations
Shifting the balance of care: great expectations
Ā 
Automation, Employment, and Health Care
Automation, Employment, and Health Care Automation, Employment, and Health Care
Automation, Employment, and Health Care
Ā 
Public perspectives on the NHS and social care
Public perspectives on the NHS and social carePublic perspectives on the NHS and social care
Public perspectives on the NHS and social care
Ā 
Evaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeEvaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers Programme
Ā 
Ensuring success for new models of care
Ensuring success for new models of careEnsuring success for new models of care
Ensuring success for new models of care
Ā 
Effectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHSEffectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHS
Ā 
Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...
Ā 
Local and national uses of data
Local and national uses of dataLocal and national uses of data
Local and national uses of data
Ā 
Applied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillanceApplied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillance
Ā 
Engaging with data
Engaging with dataEngaging with data
Engaging with data
Ā 
Evaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics UnitEvaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics Unit
Ā 
Learning from the Care Quality Commission
Learning from the Care Quality CommissionLearning from the Care Quality Commission
Learning from the Care Quality Commission
Ā 
Real-time monitoring and the data trap
Real-time monitoring and the data trapReal-time monitoring and the data trap
Real-time monitoring and the data trap
Ā 
Monitoring quality of care: making the most of data
Monitoring quality of care: making the most of dataMonitoring quality of care: making the most of data
Monitoring quality of care: making the most of data
Ā 
Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...
Ā 
Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...
Ā 
New Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessonsNew Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessons
Ā 

Recently uploaded

VIP Call Girls Indore Kirti šŸ’ššŸ˜‹ 9256729539 šŸš€ Indore Escorts
VIP Call Girls Indore Kirti šŸ’ššŸ˜‹  9256729539 šŸš€ Indore EscortsVIP Call Girls Indore Kirti šŸ’ššŸ˜‹  9256729539 šŸš€ Indore Escorts
VIP Call Girls Indore Kirti šŸ’ššŸ˜‹ 9256729539 šŸš€ Indore Escortsaditipandeya
Ā 
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual NeedsBangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual NeedsGfnyt
Ā 
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...narwatsonia7
Ā 
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...Garima Khatri
Ā 
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls ServiceKesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Servicemakika9823
Ā 
šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...
šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...
šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...Taniya Sharma
Ā 
Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...
Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...
Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...CALL GIRLS
Ā 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escortsvidya singh
Ā 
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...narwatsonia7
Ā 
Aspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas AliAspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas AliRewAs ALI
Ā 
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...Miss joya
Ā 
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...Call girls in Ahmedabad High profile
Ā 
(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...
(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...
(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...Taniya Sharma
Ā 
Call Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night EnjoyCall Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoybabeytanya
Ā 
VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...jageshsingh5554
Ā 
Call Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night EnjoyCall Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoybabeytanya
Ā 
CALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune) Girls Service
CALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune)  Girls ServiceCALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune)  Girls Service
CALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune) Girls ServiceMiss joya
Ā 
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...Miss joya
Ā 

Recently uploaded (20)

VIP Call Girls Indore Kirti šŸ’ššŸ˜‹ 9256729539 šŸš€ Indore Escorts
VIP Call Girls Indore Kirti šŸ’ššŸ˜‹  9256729539 šŸš€ Indore EscortsVIP Call Girls Indore Kirti šŸ’ššŸ˜‹  9256729539 šŸš€ Indore Escorts
VIP Call Girls Indore Kirti šŸ’ššŸ˜‹ 9256729539 šŸš€ Indore Escorts
Ā 
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual NeedsBangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Ā 
Escort Service Call Girls In Sarita Vihar,, 99530Ā°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530Ā°56974 Delhi NCREscort Service Call Girls In Sarita Vihar,, 99530Ā°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530Ā°56974 Delhi NCR
Ā 
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...Bangalore Call Girls Hebbal Kempapura Number 7001035870  Meetin With Bangalor...
Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...
Ā 
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
Ā 
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls ServiceKesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Ā 
šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...
šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...
šŸ’ŽVVIP Kolkata Call Girls ParganasšŸ©±7001035870šŸ©±Independent Girl ( Ac Rooms Avai...
Ā 
Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...
Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...
Call Girls Service Surat Samaira ā¤ļøšŸ‘ 8250192130 šŸ‘„ Independent Escort Service ...
Ā 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Ā 
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
Ā 
Aspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas AliAspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas Ali
Ā 
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
Ā 
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Ā 
(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...
(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...
(šŸ‘‘VVIP ISHAAN ) Russian Call Girls Service Navi MumbaišŸ–•9920874524šŸ–•Independent...
Ā 
Call Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night EnjoyCall Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Vashi MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Ā 
VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony šŸ“³ 7877925207 For 18+ VIP Call Girl At Th...
Ā 
Call Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night EnjoyCall Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Call Girl Number in Panvel MumbaišŸ“² 9833363713 šŸ’ž Full Night Enjoy
Ā 
CALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune) Girls Service
CALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune)  Girls ServiceCALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune)  Girls Service
CALL ON āž„9907093804 šŸ” Call Girls Hadapsar ( Pune) Girls Service
Ā 
sauth delhi call girls in Bhajanpura šŸ” 9953056974 šŸ” escort Service
sauth delhi call girls in Bhajanpura šŸ” 9953056974 šŸ” escort Servicesauth delhi call girls in Bhajanpura šŸ” 9953056974 šŸ” escort Service
sauth delhi call girls in Bhajanpura šŸ” 9953056974 šŸ” escort Service
Ā 
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Ā 

Carol Propper: Reform and demand response in the NHS

  • 1. Introduction Institutional Facts Data The Model Results Summary and Conclusions Free to Choose? Reform and Demand Response in the British National Health Service Martin Gaynorāˆ— Carol Propper Stephan Seiler āˆ—Carnegie Mellon University, University of Bristol and NBER Imperial College, University of Bristol and CEPR Stanford University and CEPR Nuļ¬ƒeld Trust 13 September 2013 Gaynor, Propper, Seiler Free to Choose? Page 1 out of 48
  • 2. Introduction Institutional Facts Data The Model Results Summary and Conclusions Questions What We Do Big Question What is impact of competition on quality in health care markets? US relies on marketsand reforms outside the US seek to expand choice using markets. Big deal - quality of care can have a big impact on welfare. We know something about the impact of market structure on quality (e.g., Kessler and McClellan, 2000; Cutler, Huckman, Kolstad, 2010; Cooper, Gibbons, Jones, McGuire, 2010; Gaynor, Moreno- Serra, Propper, 2010). But donā€™t know much about the mechanisms by which this occurs. Gaynor, Propper, Seiler Free to Choose? Page 2 out of 48
  • 3. Introduction Institutional Facts Data The Model Results Summary and Conclusions Questions What We Do Big Question cont In economic models standard that ļ¬rmsā€™ demands become more elastic with the # of ļ¬rms, i.e. with more consumer choice. A necessary condition for competition to get tougher with the # of ļ¬rms. Many policies rest on assumption that choice will provide beneļ¬ts by forcing providers to compete for patients and so respond to consumer preferences. But little direct testing of this. Gaynor, Propper, Seiler Free to Choose? Page 3 out of 48
  • 4. Introduction Institutional Facts Data The Model Results Summary and Conclusions Questions What We Do Our Question Directly examine whether demand becomes more elastic in response to increased choice. Exploit a policy change in English NHS that mandated expanded choices for consumers. Prices are regulated so choice is driven by non-price attributes, in particular, quality of care. Not obvious that increased choice will make demand more responsive to quality. switching costs; non-rational decisions (e.g. status quo bias); lack of/poor information Previous evidence on demand responsiveness to quality. Luft, Garnick, Mark, Peltzman, Phibbs, Lichtenberg, McPhee, (1990), Tay (2003), Howard (2005), Sivey (2008). Gaynor, Propper, Seiler Free to Choose? Page 4 out of 48
  • 5. Introduction Institutional Facts Data The Model Results Summary and Conclusions Questions What We Do What We Do Use individual data on patient choice of hospital for CABG surgery in the English NHS before and after the reform to estimate responsiveness of choice to quality (mortality, waiting time). Hospital discharge data from the NHS. Multinomial logit model with heterogeneity. Risk adjust mortality; instrument for waiting time. No supply side. Gaynor, Propper, Seiler Free to Choose? Page 5 out of 48
  • 6. Introduction Institutional Facts Data The Model Results Summary and Conclusions Questions What We Do We Find Patients value lower mortality rates, lower waiting times, less distance. Allowing for heterogeneity No diļ¬€erence in eļ¬€ect of mortality rates on demand pre- and post-reform on average, but sicker patients more responsive to quality post-reform. The eļ¬€ect of waiting time on demand is smaller post reform. Sicker patients are less responsive to waiting times post-reform, poorer patients are more responsive. Hospitals are spatially diļ¬€erentiated. Distance negatively aļ¬€ects demand and cross-elasticities with respect to quality fall with distance between hospitals. Gaynor, Propper, Seiler Free to Choose? Page 6 out of 48
  • 7. Introduction Institutional Facts Data The Model Results Summary and Conclusions The Reform CABG Surgery The Reform Reforms in English NHS in 2006 designed to promote patient choice and competition among hospitals. ā€œChoose and Bookā€: Mandated that patients oļ¬€ered choice of 5 hospitals. Pre-reform patients referred to hospital with which their local HA had a contract. 30% of patients aware of choice in 2006; 50% in 2009. ā€œPbRā€: Hospitals paid ļ¬xed, regulated prices (analogous to PPS). Pre-reform local health authorities negotiated contracts with hospitals (price, volume, waiting time). Hospitals classiļ¬ed as Foundation Trusts allowed to keep surpluses. Hospitals designated FTs on performance (ļ¬nancial, waiting times). Gaynor, Propper, Seiler Free to Choose? Page 7 out of 48
  • 8. Introduction Institutional Facts Data The Model Results Summary and Conclusions The Reform CABG Surgery The Reform summary Patients provided with more choices, both via Choose and Book and end of selective contracting. Hospitals moved from negotiated price environment to regulated price environment. Hospitals have incentives for ļ¬nancial performance. Gaynor, Propper, Seiler Free to Choose? Page 8 out of 48
  • 9. Introduction Institutional Facts Data The Model Results Summary and Conclusions The Reform CABG Surgery CABG Surgery Coronary artery bypass graft surgery. Treatment for coronary artery disease Frequently performed elective treatment (āˆ¼13K patients per year). Risky so mortality rate relevant and observable measure of quality of care. Referral Patients in NHS with coronary artery disease or angina are referred to a cardiologist. Referral for CABG surgery typically made by cardiologist (possibly by GP). Market 28, 29 hospitals oļ¬€er CABG (out of āˆ¼160). Market is national (England). Patients pay nothing. Gaynor, Propper, Seiler Free to Choose? Page 9 out of 48
  • 10. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Data Inpatient discharge data set for all NHS hospitals (Hospital Episode Statistics, HES). All CABG patients treated in NHS hospitals (private providers not relevant). Diagnoses, procedures, patient post code, hospital location, patient characteristics (age, sex, co-morbidities), time between referral and treatment (waiting time), patient mortality within 30 days of treatment, elective treatment. Merge area characteristics. Use elective CABGs (75% of total). Pre-reform: ļ¬scal years 2003/04, 2004/05. Post-reform: ļ¬scal years 2006/07, 2007/08. Gaynor, Propper, Seiler Free to Choose? Page 10 out of 48
  • 11. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Descriptive Statistics ā€“ Patients Standard 10th 90th Mean Median Deviation Percentile Percentile Age 65.76 66 55.04 53 76 Index of Multiple 0.14 0.1 0.11 0.04 0.31 Deprivation Comorbidity Count 5.42 5 2.81 2 9 Capped Comorbidity 4.57 5 1.61 2 6 Count (Cap = 6) Probability of Informed- 0.53 0.53 0.07 0.45 0.63 ness About Choice Fraction Male 81.18% Gaynor, Propper, Seiler Free to Choose? Page 11 out of 48
  • 12. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Descriptive Statistics ā€“ Hospitals Total Admissions Waiting Times CABGs (Days) Mean Std Mean Std 2003 502.9 189.4 109.1 32.1 2004 507.5 200.0 100.5 20.7 2005 449.1 170.8 67.8 15.2 2006 425.4 172.7 65.6 17.3 2007 459.9 169.9 64.9 21.4 Gaynor, Propper, Seiler Free to Choose? Page 12 out of 48
  • 13. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Descriptes Statistics ā€“ Hospitals Continued Mortality Rate Adjusted Mortality CABGs Rate, CABGs Mean Std Mean Std 2003 1.88 0.82 1.67 1.39 2004 1.93 0.78 1.46 1.45 2005 1.90 0.57 1.19 1.14 2006 1.95 0.79 1.40 1.18 2007 1.51 0.69 0.73 0.90 Gaynor, Propper, Seiler Free to Choose? Page 13 out of 48
  • 14. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Descriptive Statistics ā€“ Distance Standard Mean Median Deviation 10% 90% 95% Distance Pre 34.93 22.34 44.97 4.77 71.40 98.15 Post 32.24 22.91 32.94 4.93 70.58 92.36 Fraction of Patients Visiting Closest Hospital Pre 68.14 Post 68.67 Gaynor, Propper, Seiler Free to Choose? Page 14 out of 48
  • 15. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Patterns in the Data Are patterns consistent with reforms having an impact? Do better hospitals have higher market shares after introduction of choice? Regress case-mix adjusted hospital mortality rates and hospital ļ¬xed eļ¬€ects on hospital market shares pre- and post-reform, for elective and for emergency CABG (placebo test). Mortality rates are negatively related to market share post- reform for elective CABG. No signiļ¬cant relationship pre-reform for elective CABG or at all for emergency CABG. Gaynor, Propper, Seiler Free to Choose? Page 15 out of 48
  • 16. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Mortality Rates and Market Shares ā€“ Elective CABGs (1) (2) (3) (4) Dependent variable Elective CABGs Market-share Time period Pre Post Pre Post Coeļ¬ƒcient 0.0042 -0.1652** 0.0416 -0.0692* on Case-Mix Adjusted (0.0552) (0.0622) (0.0267) (0.0321) Mortality Rate Hospital Fixed Eļ¬€ects No No Yes Yes Number of Observations 142 143 142 143 Hospitals 29 29 29 29 Quarters 5 5 5 5 Gaynor, Propper, Seiler Free to Choose? Page 16 out of 48
  • 17. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Mortality Rates and Market Shares ā€“ Emergency CABGs (5) (6) (7) (8) Dependent variable Emergency CABGs Market-share Time period Pre Post Pre Post Coeļ¬ƒcient 0.0488 -0.0667 -0.0373 -0.0127 on Case-Mix Adjusted (0.0531) (0.0744) (0.0379) (0.0466) Mortality Rate Hospital Fixed Eļ¬€ects No No Yes Yes Number of Observations 142 143 142 143 Hospitals 29 29 29 29 Quarters 5 5 5 5 Gaynor, Propper, Seiler Free to Choose? Page 17 out of 48
  • 18. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Patterns in the Data 2 Did the mortality rate drop after the introduction of choice? Yes Did the mortality rate drop more for patients who bypass the nearest hospital? Yes ā€“ consistent with patients exercising more choice. Gaynor, Propper, Seiler Free to Choose? Page 18 out of 48
  • 19. Introduction Institutional Facts Data The Model Results Summary and Conclusions Descriptive Statistics Changes in the Expected Mortality Rate Mortality Rate ā€“ Case-Mix Adjusted All Patients 1.471 0.748 -0.723 Patients Visiting Nearest Hospital 1.352 0.809 -0.543 Patients Not Visiting Nearest Hosp. 1.716 0.606 -1.110 Gaynor, Propper, Seiler Free to Choose? Page 19 out of 48
  • 20. Introduction Institutional Facts Data The Model Results Summary and Conclusions Hospital Choice Correlations Modelling Approach 2 parts to econometric model Hospital choice as a function of hospital characteristics/dimensions of service (quality, waiting times, distance) Use hospital production function for quality of clinical care to overcome endogeneity of mortality rates Focus is demand model ā€“ pin down how sensitive hospital choice decisions are to quality of care Allow for patient level heterogeneity and unobserved heterogeneity at hospital level Agency Physician plays a major role in hospital choice ā€“ canā€™t separately identify patient and physician preferences Not an issue for identifying impact of reform on hospital choice Physicians in NHS salaried ā€“ no ļ¬nancial incentive wrt referrals Gaynor, Propper, Seiler Free to Choose? Page 20 out of 48
  • 21. Introduction Institutional Facts Data The Model Results Summary and Conclusions Hospital Choice Correlations Choice Model Patient i chooses hospital j to visit in time period t which provides the maximum utility according to: Vijt = Ī²w,itWjt + Ī²z,itZjt + f (Dij) + Ī¾jt + Īµijt where: W is waiting time, Z is the hospitalā€™s mortality rate, D is the distance from patient i to hospital j. Ī¾jt is unobserved hospital quality, Īµijt is a random iid shock distributed Type I Extreme Value. We allow for heterogeneity across patients in preferences for observables and unobservables. Gaynor, Propper, Seiler Free to Choose? Page 21 out of 48
  • 22. Introduction Institutional Facts Data The Model Results Summary and Conclusions Hospital Choice Correlations Choice Model, contā€™d. Allow impacts of quality of care and waiting times to diļ¬€er across patients and before and after the reform Gaynor, Propper, Seiler Free to Choose? Page 22 out of 48
  • 23. Introduction Institutional Facts Data The Model Results Summary and Conclusions Hospital Choice Correlations Correlation May be correlations between waiting times or mortality rates and unobserved hospital quality. Unobservably better hospitals may attract more patients and thus have longer waiting times. Unobservably better hospitals may attract sicker patients and thus have higher mortality rates. Deal with both - assume distance (dij) is uncorrelated with unobserved hospital quality (Ī¾j), i.e. patients donā€™t choose where to live based on hospitalsā€™ quality of care for CABG surgery. Gaynor, Propper, Seiler Free to Choose? Page 23 out of 48
  • 24. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates First Step Estimates We ļ¬nd: Sicker patients are sensitive to hospital mortality rates and more sensitive after choice reform. ā€œLow incomeā€ patients more sensitive to waiting times after choice reform. ā€œInformedā€ patients more sensitive to waiting times. Distance matters. Gaynor, Propper, Seiler Free to Choose? Page 24 out of 48
  • 25. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates First Step Estimates Coeļ¬ƒcient Stand. Error Income Waiting Pre 0.01 0.68 Deprivation Times Post -3.85 0.65 ** Index Mortality Pre 0.12 0.86 Rate Post -0.02 1.13 Co- Waiting Pre 5.67 0.43 ** Morbidity Times Post 4.10 0.58 ** Count Mortality Pre -10.11 0.56 ** Rate Post -13.18 0.94 ** Patient Waiting Pre 1.25 0.66 * Informedness Times Post -4.41 0.65 ** Mortality Pre 5.17 0.83 ** Rate Post 0.01 1.06 Unobserved Waiting Pre -0.22 75.36 Preference Times Post -0.26 76.70 Heterogeneity Mortality Pre 35.02 0.87 ** Rate Post 39.04 1.81 ** Gaynor, Propper, Seiler Free to Choose? Page 25 out of 48
  • 26. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates 2nd Step Estimates ā€“ Average Eļ¬€ects Patients more responsive to mortality rates post-reform: large impact. Waiting times not signiļ¬cant either pre- or post-reform. Gaynor, Propper, Seiler Free to Choose? Page 26 out of 48
  • 27. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates 2nd Step Estimates ā€“ Av Eļ¬€ects (cont) Baseline Sensitivity Speciļ¬cation Check Average Eļ¬€ect Coeļ¬€. S.E. Coeļ¬€. S.E. Waiting Pre -4.24 3.15 0.43 4.09 Times Post 6.25 4.74 13.45 7.53 Quality Pre -4.85 3.70 -1.63 3.81 Post -12.40 4.00** -11.39 3.96** Hospital Fixed Constant Fixed Eļ¬€ects Separate Fixed Eļ¬€ects Eļ¬€ects Pre- and Post-Reform Pre- and Post-Reform Gaynor, Propper, Seiler Free to Choose? Page 27 out of 48
  • 28. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates Elasticities Calculate impact of a 1 standard deviation change in mortality rate. Calculate patient and hospital level elasticities using the parameter estimates. Patients Large increases in responsiveness, elasticities small. Hospitals Large increases in responsiveness. Elasticities small (but larger than patient). Gaynor, Propper, Seiler Free to Choose? Page 28 out of 48
  • 29. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates Patientā€“Level Elasticities of Demand Impact on Patientā€™s Choice Probability From 1 S.D. Shift in Adjusted Mortality Elasticity Average Patient -2.69 -0.021 Pre-Reform Lower Income -2.63 -0.021 Higher Comorb -8.30 -0.066 More Informed 0.18 0.001 Average Patient -7.08 -0.056 Post-Reform Lower Income -7.09 -0.056 Higher Comorb -14.40 -0.114 More Informed -7.08 -0.056 Gaynor, Propper, Seiler Free to Choose? Page 29 out of 48
  • 30. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates Hospital Elasticities 1-S.D. Shift Mean S.D. 25th Perc. Median 75th Perc. Pre-Reform -0.36 5.11 -1.73 0.11 0.56 Post-Reform -4.83 4.73 -5.66 -3.14 -2.34 Change -5.38 5.81 -6.25 -2.88 -2.28 Elasticities Mean S.D. 25th Perc. Median 75th Perc. Pre-Reform 0.02 0.16 -0.03 0.00 0.01 Post-Reform -0.12 0.07 -0.16 -0.10 -0.05 Change -0.14 0.19 -0.15 -0.07 -0.05 Gaynor, Propper, Seiler Free to Choose? Page 30 out of 48
  • 31. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates Policy Evaluations Impact of choice on patient survival. How many more people would have died absent the reform? If patients in the post-reform period were subject to pre-reform constraints and chose with pre-reform parameters. 12 more people would have died absent the reform. Change in patient welfare What is impact on utility of freedom of choice? Compare utility post-reform patients received with utility they would have received if theyā€™d chosen with ā€œrestrictedā€ pre- reform choice parameters. Freeing choice led to 7.68% increase in patient welfare. Supply Side Regress change in adjusted mortality on change in demand elasticity with respect to quality. Large response of mortality rate to elasticity ā€“ consistent with a supply side response. Gaynor, Propper, Seiler Free to Choose? Page 31 out of 48
  • 32. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates Supply Side Response Dependent Variable Change in Case-Mix Adjusted Mortality Rate Change in the Elasticity -0.1296*** of Demand with Respect (0.0209) to the Mortality Rate Observations 27 Gaynor, Propper, Seiler Free to Choose? Page 32 out of 48
  • 33. Introduction Institutional Facts Data The Model Results Summary and Conclusions 1st-Step Estimates ā€“ Heterogeneity 2nd-Step Estimates Spatial Diļ¬€erentiation Calculate cross-elasticities with respect to mortality rate for every pair of hospitals (both directions), graphed against distance between the two hospitals. Ā  Ā  Ā  Ā  Ā  Ā  -6-4-202 log_elast 1 2 3 4 5 6 log_dist Hospitals nearby are close substitutes, little competition with far away hospitals. Gaynor, Propper, Seiler Free to Choose? Page 33 out of 48
  • 34. Introduction Institutional Facts Data The Model Results Summary and Conclusions Summary and Conclusions Test one of basic premises of competitive models ā€“ that demand elasticity increases with choice. Find that it does and there is substantial heterogeneity in consumer response. More severely ill patients become more sensitive to quality of care post-reform. No evidence that lower income patients chose lower quality hospitals post reform. Implies that the NHS reforms had an impact on demand, a necessary condition for competition. Sheds some light on the results from previous studies. Choice and competition can play an important role in health care. Gaynor, Propper, Seiler Free to Choose? Page 34 out of 48
  • 35. Introduction Institutional Facts Data The Model Results Summary and Conclusions Thank you Gaynor, Propper, Seiler Free to Choose? Page 35 out of 48
  • 36. Introduction Institutional Facts Data The Model Results Summary and Conclusions Choice Model Patient i chooses hospital j to visit in time period t which provides the maximum utility according to: Vijt = Ī²w,itWjt + Ī²z,itZjt + f (Dij) + Ī¾jt + Īµijt where: W is waiting time, Z is the hospitalā€™s mortality rate, D is the distance from patient i to hospital j. Ī¾jt is unobserved hospital quality, Īµijt is a random iid shock distributed Type I Extreme Value. We allow for heterogeneity across patients in preferences for observables and unobservables. Gaynor, Propper, Seiler Free to Choose? Page 36 out of 48
  • 37. Introduction Institutional Facts Data The Model Results Summary and Conclusions Choice Model, contā€™d. Allow impacts of quality of care and waiting times to diļ¬€er across patients and before and after the reform Ī²z,it = [Ī²z,0 + Ī²z,0Xi + Ļƒz,0vz,i] Ā· 1(t = 0) +[Ī²z,1 + Ī²z,1Xit + Ļƒz,1vz,i] Ā· 1(t = 1). Ī²w,it = [Ī²w,0 + Ī²w,0Xi + Ļƒw,0vw,i] Ā· 1(t = 0) +[Ī²w,1 + Ī²w,1Xi + Ļƒw,1vw,i] Ā· 1(t = 1) where (t = 0) is pre-reform time period, (t = 1) is post-reform, Ī²z,t is average eļ¬€ect across consumers in period t, Xi is observable patient demographics, Ī²z,t captures diļ¬€erences from the average eļ¬€ect across consumers, Ļƒz,t captures unobserved heterogeneity.Gaynor, Propper, Seiler Free to Choose? Page 37 out of 48
  • 38. Introduction Institutional Facts Data The Model Results Summary and Conclusions Waiting Times Hospitals with higher unobserved quality will have greater demand, and therefore higher waiting times. Could use IV or control for unobserved heterogeneity via ļ¬xed eļ¬€ects to absorb the variation in Ī¾jt. No obvious good instrument so we use hospital-quarter ļ¬xed eļ¬€ects i.e. time varying ļ¬xed eļ¬€ects. Cost to this: have to use two-step approach to identify average eļ¬€ects (almost 300 ļ¬xed eļ¬€ects). Gaynor, Propper, Seiler Free to Choose? Page 38 out of 48
  • 39. Introduction Institutional Facts Data The Model Results Summary and Conclusions Production Function for Clinical Quality of Care Use hospitalā€™s mortality rate for CABG patients as measure of the quality of care. Use the production function to deliver an appropriate measure of quality of care for demand model. Linear probability model of mortality: M = JTĻˆ + Hobs Ī³obs + Hunobs Ī³unobs + Ī· where M is mortality, JT is a matrix of hospital-time period dummy variables, Hobs is a matrix of patient characteristics that capture observable health status. Hunobs is unobserved health status. Gaynor, Propper, Seiler Free to Choose? Page 39 out of 48
  • 40. Introduction Institutional Facts Data The Model Results Summary and Conclusions Correlation Issue - better hospitals attract sicker patients leading to a correlation with the error. Very similar to problem of hospital mortality rates being ā€œcontaminatedā€ by diļ¬€erences in patient case-mix. Implies need to control for patientā€™s health status. Follow Gowrisankaran and Town (1999): instrument for the hospital dummies using distance. Use distance and dummies for closest hospital: 2 Ɨ as many instruments as hospital dummies. Estimate as linear probability model. Use the IV estimates of Ė†Ļˆjt as our risk-adjusted measure of the hospital mortality rate. Gaynor, Propper, Seiler Free to Choose? Page 40 out of 48
  • 41. Introduction Institutional Facts Data The Model Results Summary and Conclusions First Step contā€™d. Coeļ¬ƒcient S. E. Distance Linear -14.86 0.21 ** Square 4.91 0.11 ** Cube -0.57 0.02 ** Closest Dummy 1.07 0.02 ** Closest ā€Plus 10ā€ Dummy -0.01 0.00 * Closest ā€Plus 20ā€ Dummy 0.01 0.05 Gaynor, Propper, Seiler Free to Choose? Page 41 out of 48
  • 42. Introduction Institutional Facts Data The Model Results Summary and Conclusions Demand with Heterogeneity and Hospital Fixed Eļ¬€ects Time Period Pre-Reform Post-Reform Waiting Time -0.022 -0.020 (0.014) (0.015) Mortality Rate (Adjusted) -0.003 -0.007 (0.004) (0.006) Error From First Stage 0.027* (Control Function) (0.014) Waiting Time 0.028*** 0.025*** * Comorbidity Count (0.002) (0.003) Mortality Rate (Adjusted) -0.021*** -0.060*** * Comorbidity Count (0.002) (0.004) Waiting Time -0.040 -0.336*** * IMD Index (0.033) (0.044) Mortality Rate (Adjusted) 0.035 0.060 * IMD Index (0.034) (0.049) Observations 51,793 Gaynor, Propper, Seiler Free to Choose? Page 42 out of 48
  • 43. Introduction Institutional Facts Data The Model Results Summary and Conclusions IV Mortality Rate Model In order to obtain adjusted mortality rates we run a linear probability model, regressing a dummy for death on a set of quarter-speciļ¬c hospital dummies. The hospital dummies are stacked in a block-diagonal matrix, each block representing one quarter out of 20 quarter for the time period 2001 to 2005. The case-mix is restricted to enter in the same way in all quarters. Speciļ¬cally, the data are arranged as follows: X = ļ£® ļ£Æ ļ£Æ ļ£Æ ļ£° X1 CM1 X2 CM2 ... ... X20 CM20 ļ£¹ ļ£ŗ ļ£ŗ ļ£ŗ ļ£» Gaynor, Propper, Seiler Free to Choose? Page 43 out of 48
  • 44. Introduction Institutional Facts Data The Model Results Summary and Conclusions IV Mortality Rate Model Contā€™d. Where CMt denotes a matrix with various variables capturing the health status of patients within a particular quarter t. All elements in the matrix other then the matrices X1 to X20 and CM1 to CM20 are equal to zero. The block-diagonal elements are given by: Xt = ļ£® ļ£Æ ļ£° xt 11 Ā· Ā· Ā· xt 1kt ... ... ... xt nt1 Ā· Ā· Ā· xt ntkt ļ£¹ ļ£ŗ ļ£» Where nt denotes the number of patients in a particular quarter t, i.e. the number of observations in the data. kt denotes the number of hospital dummies in each quarter. This number varies across quarters because of hospital entry, exit and mergers. Gaynor, Propper, Seiler Free to Choose? Page 44 out of 48
  • 45. Introduction Institutional Facts Data The Model Results Summary and Conclusions IV Mortality Rate Model Contā€™d. The matrix of instruments is arranged in a similar fashion: Z = ļ£® ļ£Æ ļ£Æ ļ£Æ ļ£° Z1 CM1 Z2 CM2 ... ... Z20 CM20 ļ£¹ ļ£ŗ ļ£ŗ ļ£ŗ ļ£» with Zt = ļ£® ļ£Æ ļ£° zt 11 Ā· Ā· Ā· zt 1lt ... ... ... zt nt1 Ā· Ā· Ā· zt ntlt ļ£¹ ļ£ŗ ļ£» Gaynor, Propper, Seiler Free to Choose? Page 45 out of 48
  • 46. Introduction Institutional Facts Data The Model Results Summary and Conclusions IV Mortality Rate Model Contā€™d. Where nt denotes the number of patients in a particular quarter t (as in the X-matrix above). lt denotes the number of quarter- speciļ¬c instruments. In general we need the condition lt > kt āˆ’ 1 to be fulļ¬lled in all quarters (We do not need an instrument for the constant in each quarter, i.e. the average quarterly death rate over all hospitals). In practice we use the distance to each hospital available in the quarter and a dummy for whether this is the closest hospital for the individual patient as instruments. This yields lt = 2 āˆ— kt instruments for each quarter. Gaynor, Propper, Seiler Free to Choose? Page 46 out of 48
  • 47. Introduction Institutional Facts Data The Model Results Summary and Conclusions Changes in Survival Probability due to the Reform Change in Survival when Choices Post-Reform -12.17 are Made with Pre-Reform Parameters Post-Reform Admissions 20338 (5 Quarters) Deaths 393 Mortality Rate 1.93 Recomputed Mortality Rate 1.87 Gaynor, Propper, Seiler Free to Choose? Page 47 out of 48
  • 48. Introduction Institutional Facts Data The Model Results Summary and Conclusions Hospital Selection Based on Severity Adjusted Adjusted Dependent Variable Mortality Rate Mortality Rate Co-morbidity Count -0.220** -0.180** (0.006) (0.006) Quarter Fixed Eļ¬€ects No Yes (Flexible Time Trend) Number of Observations 32,715 32,715 Gaynor, Propper, Seiler Free to Choose? Page 48 out of 48